 | - 4 to be charged in record ecstasy case, PG decides
(Aug 06, 2007)
- Deadlock at Rosh Pinah
(Aug 06, 2007)
- Computer theft ring cracked
(Aug 06, 2007)
- Our Nicolas Sarkozy must please stand up!
(May 17, 2007)
- Electricity in Namibia - Quo Vadis?
(May 17, 2007)
- Political Perspective
(May 17, 2007)
- Attacks On Media Persist
(May 17, 2007)
- 'Not guilty', says family shooting suspect Endjala
(May 16, 2007)
- Racist backlash angers City Lutheran pastor
(May 16, 2007)
- Episode two in rugby’s Who’s the Boss?
(May 15, 2007)
|
|  |
 | - All topics
- Buisiness and Economy (May 10, 2007)
- Computer Games (May 11, 2007)
- Entertainment Music, Movies .... (Aug 06, 2007)
- Enviroment (May 17, 2007)
- General Health (May 16, 2007)
- International News (May 08, 2007)
- Namibia in the News (Aug 06, 2007)
- Namibian Elections 2004 (May 16, 2007)
- PostNuke (May 16, 2007)
- Religion (May 13, 2007)
- Science and Technology (May 16, 2007)
- Sport (May 17, 2007)
- Travel, Tourism (May 15, 2007)
|
|  |
|
|
 | | Posted by admin on Friday, March 26, 2004 - 04:35 PM |
|  |
 |  |
NEW YORK (Reuters Health) - A study of more than 9,000 children and adolescents indicates that the use of the nasal influenza vaccine (FluMist) is generally safe. However, questions still remain about the risk of reactive airway disease in certain children under the age of 3 years.
As researcher Dr. Steve Black told Reuters Health, "there was a suggestion that (such) children vaccinated with (FluMist) were at increased risk for medical visits for asthma within 6 weeks following vaccine as compared to controls. However, children with asthma prior to vaccination, overall, had a lower risk of asthma visits as compared to controls."
In the Pediatric Infectious Disease Journal, Black of the Kaiser Permanente Vaccine Study Center in Oakland, California, and colleagues note that they came to these conclusions after a trial of the nasal flu vaccine in children between 1 and 17 years old.
All received at least one dose of vaccine or placebo. Those 8 years or younger received a second dose 28 to 42 days later. All children were followed for 42 days after each vaccination.
Following evaluation of 9,689 children, there appeared to be no association between vaccination and acute respiratory tract infections, systemic bacterial infection, acute GI complaints, and those potentially associated with influenza.
However, in children aged 18 to 35 months there was a four-fold increased risk of reactive airway disease.
Thus, continued Dr. Black, "our conclusion was that the risk of asthma following (nasal flu vaccination) in children less than three years old needed further evaluation prior to the use of the vaccine in that age group."
They theorize that if this increased risk is confirmed in another study, it may be that these children have never been exposed to an influenza virus "and might respond to this vaccine differently because of this."
| |
|  |
|
|
|
|